Venous Congestion, Endothelial and Neurohormonal Activation in Acute Decompensated Heart Failure: Cause or Effect?

Current Heart Failure Reports

Volumn 12, Issue 3, 2015, Pages 215-222

  Colombo, Paolo C ^a   Doran, Amanda C ^a   Onat, Duygu ^a   Wong, Ka Yuk ^a   Ahmad, Myra ^a   Sabbah, Hani N ^b   Demmer, Ryan T ^c  

^a Columbia University ^*  (United States)

^b HENRY FORD HEART AND VASCULAR INSTITUTE   (United States)

^c NONE   (United States)

Author keywords

Endothelial; Heart failure

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

ACUTE DISEASE; ANIMAL; COMPLICATION; DISEASE MODEL; HEART FAILURE; HUMAN; HYPEREMIA; MECHANICAL STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ACUTE DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HEART FAILURE; HUMANS; HYPEREMIA; NEUROTRANSMITTER AGENTS; STRESS, MECHANICAL;

EID: 84939939154     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-015-0254-8     Document Type: Review

References (74)

1. Allen LA, Metra M, Milo-Cotter O, Filippatos G, Reisin LH, Bensimhon DR, et al. Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of Measures of Disease Severity in Acute Heart Failure (MEASURE-AHF). J Card Fail. 2008;14(9):777–84. doi:10.1016/j.cardfail.2008.07.188.
2. Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol. 2009;53(7):582–8. doi:10.1016/j.jacc.2008.08.080.
3. Felker GM, Adams Jr KF, Konstam MA, O’Connor CM, Gheorghiade M. The problem of decompensated heart failure: nomenclature, classification, and risk stratification. Am Heart J. 2003;145(2 Suppl):S18–25. doi:10.1067/mhj.2003.150.
4. Fonarow GC, Abraham WT, Albert NM, Gattis Stough W, Gheorghiade M, Greenberg BH, et al. Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Arch Intern Med. 2007;167(14):1493–502. doi:10.1001/archinte.167.14.1493.
5. Fonarow GC, Heywood JT, Heidenreich PA, Lopatin M, Yancy CW. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2007;153(6):1021–8. doi:10.1016/j.ahj.2007.03.012.
6. Gheorghiade M, Filippatos G, De Luca L, Burnett J. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am J Med. 2006;119(12 Suppl 1):S3–10. doi:10.1016/j.amjmed.2006.09.011.
7. Gheorghiade M, Gattis WA, O’Connor CM, Adams Jr KF, Elkayam U, Barbagelata A, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291(16):1963–71. doi:10.1001/jama.291.16.1963.
8. Gheorghiade M, Zannad F, Sopko G, Klein L, Pina IL, Konstam MA, et al. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005;112(25):3958–68. doi:10.1161/CIRCULATIONAHA.105.590091.
9. Lucas C, Johnson W, Hamilton MA, Fonarow GC, Woo MA, Flavell CM, et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J. 2000;140(6):840–7. doi:10.1067/mhj.2000.110933.
10. Cotter G, Metra M, Milo-Cotter O, Dittrich HC, Gheorghiade M. Fluid overload in acute heart failure—re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail. 2008;10(2):165–9. doi:10.1016/j.ejheart.2008.01.007.
11. Dorhout Mees EJ. Diastolic heart failure: a confusing concept. Heart Fail Rev. 2013;18(4):503–9. doi:10.1007/s10741-012-9344-9.
12. Felker GM, Cotter G. Unraveling the pathophysiology of acute heart failure: an inflammatory proposal. Am Heart J. 2006;151(4):765–7. doi:10.1016/j.ahj.2005.07.004.
13. Yu CM, Wang L, Chau E, Chan RH, Kong SL, Tang MO, et al. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation. 2005;112(6):841–8. doi:10.1161/CIRCULATIONAHA.104.492207.
14. Tsutamoto T, Hisanaga T, Fukai D, Wada A, Maeda Y, Maeda K, et al. Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure. Am J Cardiol. 1995;76(11):803–8.
15. Andreassen AK, Nordoy I, Simonsen S, Ueland T, Muller F, Froland SS, et al. Levels of circulating adhesion molecules in congestive heart failure and after heart transplantation. Am J Cardiol. 1998;81(5):604–8.
16. Klein RM, Breuer R, Mundhenke M, Schwartzkopff B, Strauer BE. Circulating adhesion molecules (cICAM-1, lcVCAM-1) in patients with suspected inflammatory heart muscle disease. Z Kardiol. 1998;87(2):84–93.
17. Yin WH, Chen JW, Jen HL, Chiang MC, Huang WP, Feng AN, et al. The prognostic value of circulating soluble cell adhesion molecules in patients with chronic congestive heart failure. Eur J Heart Fail. 2003;5(4):507–16.
18. Bonomini M, Reale M, Santarelli P, Stuard S, Settefrati N, Albertazzi A. Serum levels of soluble adhesion molecules in chronic renal failure and dialysis patients. Nephron. 1998;79(4):399–407.
19. Munger MA, Johnson B, Amber IJ, Callahan KS, Gilbert EM. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1996;77(9):723–7.
20. Testa M, Yeh M, Lee P, Fanelli R, Loperfido F, Berman JW, et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol. 1996;28(4):964–71.
21. Packer M. Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure? Circulation. 1995;92(6):1379–82.
22. Carlstedt F, Lind L, Lindahl B. Proinflammatory cytokines, measured in a mixed population on arrival in the emergency department, are related to mortality and severity of disease. J Intern Med. 1997;242(5):361–5.
23. Matsumoto M, Tsujino T, Lee-Kawabata M, Naito Y, Sakoda T, Ohyanagi M, et al. Serum interleukin-6 and C-reactive protein are markedly elevated in acute decompensated heart failure patients with left ventricular systolic dysfunction. Cytokine. 2010;49(3):264–8. doi:10.1016/j.cyto.2009.11.006.
24. Barreto DV, Barreto FC, Liabeuf S, Temmar M, Lemke HD, Tribouilloy C, et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int. 2010;77(6):550–6. doi:10.1038/ki.2009.503.
25. Descamps-Latscha B, Herbelin A, Nguyen AT, Roux-Lombard P, Zingraff J, Moynot A, et al. Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. J Immunol. 1995;154(2):882–92.
26. Francis SE, Holden H, Holt CM, Duff GW. Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy. J Mol Cell Cardiol. 1998;30(2):215–23. doi:10.1006/jmcc.1997.0592.
27. Sharma A, Hermann DD, Mehta RL. Clinical benefit and approach of ultrafiltration in acute heart failure. Cardiology. 2001;96(3–4):144–54.
28. Rodeheffer RJ, Lerman A, Heublein DM, Burnett Jr JC. Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin Proc. 1992;67(8):719–24.
29. Cottone S, Mule G, Guarneri M, Palermo A, Lorito MC, Riccobene R, et al. Endothelin-1 and F2-isoprostane relate to and predict renal dysfunction in hypertensive patients. Nephrol Dial Transplant. 2009;24(2):497–503. doi:10.1093/ndt/gfn489.
30. Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation. 1981;63(3):645–51.
31. Lauten A, Ferrari M, Goebel B, Rademacher W, Schumm J, Uth O, et al. Microvascular tissue perfusion is impaired in acutely decompensated heart failure and improves following standard treatment. Eur J Heart Fail. 2011;13(7):711–7. doi:10.1093/eurjhf/hfr043.
32. Paton AM, Lever AF, Oliver NW, Medina A, Briggs JD, Morton JJ, et al. Plasma angiotensin II, renin, renin-substrate and aldosterone concentrations in acute renal failure in man. Clin Nephrol. 1975;3(1):18–23.
33. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82(5):1724–9.
34. Milo O, Cotter G, Kaluski E, Brill A, Blatt A, Krakover R, et al. Comparison of inflammatory and neurohormonal activation in cardiogenic pulmonary edema secondary to ischemic versus nonischemic causes. Am J Cardiol. 2003;92(2):222–6.
35. White M, Ducharme A, Ibrahim R, Whittom L, Lavoie J, Guertin MC, et al. Increased systemic inflammation and oxidative stress in patients with worsening congestive heart failure: improvement after short-term inotropic support. Clin Sci (Lond). 2006;110(4):483–9. doi:10.1042/CS20050317.
36. Gutierrez E, Flammer AJ, Lerman LO, Elizaga J, Lerman A, Fernandez-Aviles F. Endothelial dysfunction over the course of coronary artery disease. Eur Heart J. 2013;34(41):3175–81. doi:10.1093/eurheartj/eht351.
37. Marti CN, Gheorghiade M, Kalogeropoulos AP, Georgiopoulou VV, Quyyumi AA, Butler J. Endothelial dysfunction, arterial stiffness, and heart failure. J Am Coll Cardiol. 2012;60(16):1455–69. doi:10.1016/j.jacc.2011.11.082.
38. Rajendran P, Rengarajan T, Thangavel J, Nishigaki Y, Sakthisekaran D, Sethi G, et al. The vascular endothelium and human diseases. Int J Biol Sci. 2013;9(10):1057–69. doi:10.7150/ijbs.7502.
39. Zhou J, Li YS, Chien S. Shear stress-initiated signaling and its regulation of endothelial function. Arterioscler Thromb Vasc Biol. 2014;34(10):2191–8. doi:10.1161/ATVBAHA.114.303422.
40. Mitchell JA, Ali F, Bailey L, Moreno L, Harrington LS. Role of nitric oxide and prostacyclin as vasoactive hormones released by the endothelium. Exp Physiol. 2008;93(1):141–7. doi:10.1113/expphysiol.2007.038588.
41. Cannon 3rd RO. Role of nitric oxide in cardiovascular disease: focus on the endothelium. Clin Chem. 1998;44(8 Pt 2):1809–19.
42. Drexler H. Nitric oxide synthases in the failing human heart: a doubled-edged sword? Circulation. 1999;99(23):2972–5.
43. Starling RC. Inducible nitric oxide synthase in severe human heart failure: impact of mechanical unloading. J Am Coll Cardiol. 2005;45(9):1425–7. doi:10.1016/j.jacc.2005.02.021.
44. Boo YC. Shear stress stimulates phosphorylation of protein kinase A substrate proteins including endothelial nitric oxide synthase in endothelial cells. Exp Mol Med. 2006;38(4):453. doi:10.1038/emm.2006.53.
45. Jin ZG, Ueba H, Tanimoto T, Lungu AO, Frame MD, Berk BC. Ligand-independent activation of vascular endothelial growth factor receptor 2 by fluid shear stress regulates activation of endothelial nitric oxide synthase. Circ Res. 2003;93(4):354–63. doi:10.1161/01.RES.0000089257.94002.96.
46. Hsieh HJ, Liu CA, Huang B, Tseng AH, Wang DL. Shear-induced endothelial mechanotransduction: the interplay between reactive oxygen species (ROS) and nitric oxide (NO) and the pathophysiological implications. J Biomed Sci. 2014;21:3. doi:10.1186/1423-0127-21-3.
47. Hasdai D, Holmes Jr DR, Garratt KN, Edwards WD, Lerman A. Mechanical pressure and stretch release endothelin-1 from human atherosclerotic coronary arteries in vivo. Circulation. 1997;95(2):357–62.
48. Delli Gatti C, Osto E, Kouroedov A, Eto M, Shaw S, Volpe M, et al. Pulsatile stretch induces release of angiotensin II and oxidative stress in human endothelial cells: effects of ACE inhibition and AT1 receptor antagonism. Clin Exp Hypertens. 2008;30(7):616–27. doi:10.1080/10641960802443183.
49. Cheng JJ, Wung BS, Chao YJ, Wang DL. Cyclic strain enhances adhesion of monocytes to endothelial cells by increasing intercellular adhesion molecule-1 expression. Hypertension. 1996;28(3):386–91.
50. Kawai M, Naruse K, Komatsu S, Kobayashi S, Nagino M, Nimura Y, et al. Mechanical stress-dependent secretion of interleukin 6 by endothelial cells after portal vein embolization: clinical and experimental studies. J Hepatol. 2002;37(2):240–6.
51. Wang BW, Chang H, Lin S, Kuan P, Shyu KG. Induction of matrix metalloproteinases-14 and -2 by cyclical mechanical stretch is mediated by tumor necrosis factor-alpha in cultured human umbilical vein endothelial cells. Cardiovasc Res. 2003;59(2):460–9.
52. Davies PF. Hemodynamic shear stress and the endothelium in cardiovascular pathophysiology. Nat Clin Pract Cardiovasc Med. 2009;6(1):16–26. doi:10.1038/ncpcardio1397.
53. Canty Jr TG, Boyle Jr EM, Farr A, Morgan EN, Verrier ED, Pohlman TH. Oxidative stress induces NF-kappaB nuclear translocation without degradation of IkappaBalpha. Circulation. 1999;100(19 Suppl):II361–4.
54. Boyle Jr EM, Canty Jr TG, Morgan EN, Yun W, Pohlman TH, Verrier ED. Treating myocardial ischemia-reperfusion injury by targeting endothelial cell transcription. Ann Thorac Surg. 1999;68(5):1949–53.
55. Hung TH, Charnock-Jones DS, Skepper JN, Burton GJ. Secretion of tumor necrosis factor-alpha from human placental tissues induced by hypoxia-reoxygenation causes endothelial cell activation in vitro: a potential mediator of the inflammatory response in preeclampsia. Am J Pathol. 2004;164(3):1049–61.
56. Sorescu GP, Song H, Tressel SL, Hwang J, Dikalov S, Smith DA, et al. Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress induces monocyte adhesion by stimulating reactive oxygen species production from a nox1-based NADPH oxidase. Circ Res. 2004;95(8):773–9. doi:10.1161/01.RES.0000145728.22878.45.
57. Sumpio BE, Riley JT, Dardik A. Cells in focus: endothelial cell. Int J Biochem Cell Biol. 2002;34(12):1508–12.
58. Onat D, Jelic S, Schmidt AM, Pile-Spellman J, Homma S, Padeletti M, et al. Vascular endothelial sampling and analysis of gene transcripts: a new quantitative approach to monitor vascular inflammation. J Appl Physiol. 2007;103(5):1873–8. doi:10.1152/japplphysiol.00367.2007.
59. Colombo PC, Banchs JE, Celaj S, Talreja A, Lachmann J, Malla S, et al. Endothelial cell activation in patients with decompensated heart failure. Circulation. 2005;111(1):58–62. doi:10.1161/01.CIR.0000151611.89232.3B.
60. Colombo PC, Rastogi S, Onat D, Zaca V, Gupta RC, Jorde UP, et al. Activation of endothelial cells in conduit veins of dogs with heart failure and veins of normal dogs after vascular stretch by acute volume loading. J Card Fail. 2009;15(5):457–63. doi:10.1016/j.cardfail.2008.12.006.
61. Colombo PC, Onat D, Harxhi A, Demmer RT, Hayashi Y, Jelic S, et al. Peripheral venous congestion causes inflammation, neurohormonal, and endothelial cell activation. Eur Heart J. 2014;35(7):448–54. doi:10.1093/eurheartj/eht456. This recent article provides mechanistic in vivo evidence for a link between peripheral venous congestion and activation of the inflammatory/oxidative program within endothelial cells of humans.
62. Colombo PC, Onat D, Harxhi A, Hayashi Y, Wong KY, Uriel N, et al. Acute venous congestion enhances vasoconstriction, inflammation, endothelial activation and oxidative stress in compensated ambulatory patients with systolic heart failure on an optimized medical regimen. Circulation (AHA abstract). 2014.
63. Hawk C, Hayashu Y, Kin J, Chudasama N, Ramnauth DS, Wong KY, et al. Peripheral venous congestion causes time- and dose-dependent release of endothelin-1 in humans. Circulation (AHA abstract). 2014.
64. Cui J, McQuillan P, Moradkhan R, Pagana C, Sinoway LI. Sympathetic responses during saline infusion into the veins of an occluded limb. J Physiol. 2009;587(Pt 14):3619–28. doi:10.1113/jphysiol.2009.173237. This important article demonstrates that peripheral venous congestion is sufficient to evoke systemic sympathetic activation.
65. Cui J, McQuillan PM, Blaha C, Kunselman AR, Sinoway LI. Limb venous distension evokes sympathetic activation via stimulation of the limb afferents in humans. Am J Physiol Heart Circ Physiol. 2012;303(4):H457–63. doi:10.1152/ajpheart.00236.2012.
66. Cui J, Leuenberger UA, Gao Z, Sinoway LI. Sympathetic and cardiovascular responses to venous distension in an occluded limb. Am J Physiol Regul Integr Comp Physiol. 2011;301(6):R1831–7. doi:10.1152/ajpregu.00170.2011.
67. Cui J, Gao Z, Blaha C, Herr MD, Mast J, Sinoway LI. Distension of central great vein decreases sympathetic outflow in humans. Am J Physiol Heart Circ Physiol. 2013;305(3):H378–85. doi:10.1152/ajpheart.00019.2013. This important study demonstrated that central saline infusion leads to activation of the sympathetic response, increase in blood pressure and decrease in MSNA levels.
68. Mann DL. Mechanisms and models in heart failure: a combinatorial approach. Circulation. 1999;100(9):999–1008.
69. Masoumi A, Ortiz F, Radhakrishnan J, Schrier RW, Colombo PC. Mineralocorticoid receptor antagonists as diuretics: can congestive heart failure learn from liver failure? Heart Fail Rev. 2014. doi:10.1007/s10741-014-9467-2.
70. Vlachopoulos C, Dima I, Aznaouridis K, Vasiliadou C, Ioakeimidis N, Aggeli C, et al. Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals. Circulation. 2005;112(14):2193–200. doi:10.1161/CIRCULATIONAHA.105.535435.
71. Chen X, Rahman MA, Floras JS. Effects of forearm venous occlusion on peroneal muscle sympathetic nerve activity in healthy subjects. Am J Cardiol. 1995;76(3):212–4.
72. Colombo PC, Onat D, Sabbah HN. Acute heart failure as “acute endothelitis”—interaction of fluid overload and endothelial dysfunction. Eur J Heart Fail. 2008;10(2):170–5. doi:10.1016/j.ejheart.2007.12.007.
73. Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377(9766):658–66. doi:10.1016/S0140-6736(11)60101-3. This landmark study introduces the advantages of long term invasive hemodynamic monitoring in heart failure.
74. Adamson PB, Abraham WT, Bourge RC, Costanzo MR, Hasan A, Yadav C, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail. 2014;7(6):935–44. doi:10.1161/CIRCHEARTFAILURE.113.001229. This recent article demonstrates the successful use of invasive hemodynamic monitoring for the long term management of heart failure in order to prevent heart failure hospitalizations.